Intellia Therapeutics, Inc. (NTLA)
| Market Cap | 9.75B |
| Revenue (ttm) | 41.81M |
| Net Income (ttm) | -185.04M |
| Shares Out | 68.16M |
| EPS (ttm) | -2.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 759,409 |
| Open | 130.21 |
| Previous Close | 129.14 |
| Day's Range | 130.21 - 138.48 |
| 52-Week Range | 23.49 - 202.73 |
| Beta | 2.17 |
| Analysts | Buy |
| Price Target | 175.56 (+30.8%) |
| Est. Earnings Date | Nov 4, 2021 |
About NTLA
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 ...
Financial Performance
In 2020, NTLA's revenue was $57.99 million, an increase of 34.55% compared to the previous year's $43.10 million. Losses were -$134.23 million, 34.9% more than in 2019.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is 175.56, which is an increase of 30.81% from the latest price.
News
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for ...
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities a...
CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...
Intellia Moves Into Eye Treatments With SparingVision Deal
Intellia Therapeutics Inc. ( NTLA , Financial) is following in the footsteps of several members of Big Pharma that have hooked up with smaller, specialized biotechs to develop gene therapies to treat ey...
2 Gene-Editing Stocks to Have on Your Radar Right Now
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
A key gene-editing readout had Cathie Wood shuffling her portfolio.
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRIS...
CAMBRIDGE, Mass. and PARIS, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics usin...
Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 202...
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...
Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients
The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) Phase 1/2 study of NTLA-2002 in hereditary angioedema (HAE). NTLA-2002 ...
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of H...
CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...
Intellia Therapeutics to Present at Chardan's 5th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/C...
Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients
The FDA has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) investigational new drug (IND) application for NTLA-5001. Related Content: Intellia Shares Shoot Higher On Promising Biomarker Data Fr...
Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR...
CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/C...
7 Gene Editing Stocks Promising to Change our DNA
Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared fi...
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic Rev...
Intellia Therapeutics to Present at September Healthcare Investor Conferences
CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...
New Strong Sell Stocks for August 24th
BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. The post Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and ...
Will Moderna's Interest Boost Gene Editing Stocks?
Our indicative theme of Gene Editing stocks has returned about 11% year-to-date, compared to the S&P 500 which is up by about 19% over the same period. However, the gains have overwhelmingly come from a...
Why Shares of Intellia Therapeutics Are Jumping Today
More progress in the pipeline has investors bullish on the company's shares.
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. The post Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are C...
Why Intellia Therapeutics Shares Are Trading Higher Today
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks y...
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -65.57% and -45.54%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the st...
Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Ca...